****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 18](#_Toc169093101)

[1.1 Statement of the Report 18](#_Toc169093102)

[1.2 Executive Summary 20](#_Toc169093103)

[2. INTRODUCTION 22](#_Toc169093104)

[3. CURRENT STATUS OF IPSC INDUSTRY 23](#_Toc169093105)

[3.1 Progress made in Autologous Cell Therapy using iPSCs 23](#_Toc169093106)

[3.1.1 Examples of Autologous iPSC-derived Cell Therapies in Development 25](#_Toc169093107)

[3.1.2 Manufacturing Timeline for Autologous iPSC-derived Cell Products 25](#_Toc169093108)

[3.1.3 Cost of iPSC Production 26](#_Toc169093109)

[3.1.4 Automation in iPSC Production 27](#_Toc169093110)

[3.2 Allogeneic iPSC-based Cell Therapies 29](#_Toc169093111)

[3.3 Share of iPSC-based Research within the Overall Stem Cell Industry 30](#_Toc169093112)

[3.4 Major Focus Areas of iPSC Companies 31](#_Toc169093113)

[3.5 Commercially Available iPSC-derived Cell Types 32](#_Toc169093114)

[3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays 33](#_Toc169093115)

[3.7 iPSC-derived Cell Types used in Clinical Trials 33](#_Toc169093116)

[3.8 Currently Available iPSC Technologies 34](#_Toc169093117)

[3.8.1 Brief Descriptions of some iPSC-related Technologies 36](#_Toc169093118)

[3.8.1.1 Nucleofector Technology 36](#_Toc169093119)

[3.8.1.2 Opti-ox Technology 37](#_Toc169093120)

[3.8.1.3 MOGRIFY Technology 37](#_Toc169093121)

[3.8.1.4 Transcription Factor-based iPSC Differentiation Technology 37](#_Toc169093122)

[3.8.1.5 Flowfect Technology 38](#_Toc169093123)

[3.8.1.6 Technology for Mass Production of Platelets 38](#_Toc169093124)

[3.8.1.7 SynFire Technology 38](#_Toc169093125)

[4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 39](#_Toc169093126)

[4.1 First iPSC Generation from Mouse Fibroblasts, 2006 40](#_Toc169093127)

[4.2 First Human iPSC Generation, 2007 40](#_Toc169093128)

[4.3 Creation of CiRA, 2010 40](#_Toc169093129)

[4.4 First High-Throughput Screening using iPSCs, 2012 40](#_Toc169093130)

[4.5 First iPSC Clinical Trial Approved in Japan, 2013 41](#_Toc169093131)

[4.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 2014 41](#_Toc169093132)

[4.7 EBiSC Founded, 2014 41](#_Toc169093133)

[4.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017 41](#_Toc169093134)

[4.9 Clinical Trial for Parkinson’s Disease using Allogeneic iPSCs, 2018 42](#_Toc169093135)

[4.10 Commercial iPSC Plant SMaRT Established, 2018 42](#_Toc169093136)

[4.11 First iPSC Therapy Center in Japan, 2019 42](#_Toc169093137)

[4.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 2019 42](#_Toc169093138)

[4.13 Cynata Therapeutics’ World’s Largest Phase III Clinical Trial, 2020 43](#_Toc169093139)

[4.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021 43](#_Toc169093140)

[4.15 Production of in-house iPSCs using Peripheral Blood Cells, 2022 43](#_Toc169093141)

[5. RESEARCH PUBLICATIONS ON IPSCS 45](#_Toc169093142)

[5.1 Rapid Growth in iPSC Publications 45](#_Toc169093143)

[5.1.1 PubMd Publications on Pathophysiological Research using iPSCs 47](#_Toc169093144)

[5.1.2 PubMed Papers on Reprogramming 47](#_Toc169093145)

[5.1.3 PubMed Papers on iPSC Differentiation 48](#_Toc169093146)

[5.1.4 PubMed Papers on the use of iPSCs in Drug Discovery 49](#_Toc169093147)

[5.1.5 PubMed Papers on iPSC-based Cell Therapy 50](#_Toc169093148)

[5.1.5.1 Percent Share of Published Articles by Disease Type 51](#_Toc169093149)

[5.1.5.2 Percent Share of Articles by Country 52](#_Toc169093150)

[6. IPSC: PATENT LANDSCAPE ANALYSIS 54](#_Toc169093151)

[6.1 iPSC Patent Applications by Jurisdiction 55](#_Toc169093152)

[6.2 iPSC Patent Applicants 56](#_Toc169093153)

[6.3 Inventors of iPSC Patents 59](#_Toc169093154)

[6.4 iPSC Patent Owners 62](#_Toc169093155)

[6.5 Legal Status of iPSC Patents 65](#_Toc169093156)

[7. IPSC: CLINICAL TRIAL LANDSCAPE 66](#_Toc169093157)

[7.1 Number of iPSC Clinical Trials 66](#_Toc169093158)

[7.1 Recruitment Status of iPSC Clinical Trials 67](#_Toc169093159)

[7.3 iPSC Clinical Trials Stydy Designs 67](#_Toc169093160)

[7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials 68](#_Toc169093161)

[7.4.1 Non-Therapeutic Clinical Studies by Use 69](#_Toc169093162)

[7.4.2 Diseases Targeted by Therapeutic Studies 69](#_Toc169093163)

[7.4.2.1 Therapeutic Clinical Studies by Autologous & Allogeneic Sources of iPSCs 70](#_Toc169093164)

[7.4.3 Examples of iPSC-based Therapeutic Studies 71](#_Toc169093165)

[7.5 iPSC-based Trials by Phase of Study 73](#_Toc169093166)

[7.6 iPSC Clinical Trials by Funder Type 74](#_Toc169093167)

[7.7 Geographic Distribution of iPSC-based Clinical Trials 75](#_Toc169093168)

[7.8 Promising iPSC Product Candidates 75](#_Toc169093169)

[7.8.1 CYP-001, CYP-004 & CYP-006 from Cynata Therapeutics 76](#_Toc169093170)

[7.8.2 BioVAT-HF from Repairon GmbH 77](#_Toc169093171)

[7.8.3 HS-001 from Heartseed 77](#_Toc169093172)

[7.8.4 CNTY-101 from Century Therapeutics 77](#_Toc169093173)

[7.8.5 FT-576 & FT-819 from Fate Therapeutics 77](#_Toc169093174)

[7.8.6 RPE from National Eye Institute 78](#_Toc169093175)

[7.8.7 QN-019a from Qihan Biotech 78](#_Toc169093176)

[7.8.8 iPSC-CL from Heartworks, Inc. 78](#_Toc169093177)

[7.9 Companies having Preclinical iPSC Assets 79](#_Toc169093178)

[7.9.1 Aspen Neuroscience 80](#_Toc169093179)

[7.9.2 Ryne Biotech 80](#_Toc169093180)

[7.9.2 Bluerock Therapeutics 80](#_Toc169093181)

[7.9.4 Vita Therapeutics 80](#_Toc169093182)

[7.9.5 Hopstem Biotechnology 81](#_Toc169093183)

[7.9.6 Res Nova Bio, Inc. 81](#_Toc169093184)

[7.9.7 Cytovia Therapeutics 81](#_Toc169093185)

[7.9.8 Hebecell Corporation 81](#_Toc169093186)

[7.9.9 Sana Biotechnology 82](#_Toc169093187)

[7.9.10 SCG Cell Therapy Pte 82](#_Toc169093188)

[7.9.11 Cytomed 82](#_Toc169093189)

[7.9.12 Shoreline Biosciences 82](#_Toc169093190)

[7.9.13 Neukio Biotherapeutics 82](#_Toc169093191)

[7.9.14 Exacis Biotherapeutics 83](#_Toc169093192)

[7.9.15 CellOrigin Biotech 83](#_Toc169093193)

[8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR 84](#_Toc169093194)

[8.1 Mergers and Acquisitions (M&A) Sector 84](#_Toc169093195)

[8.1.1 Century Therapeutics & Clade Therapeutics 84](#_Toc169093196)

[8.1.2 Evotech & Rigenerand 85](#_Toc169093197)

[8.1.3 Fujifilm Corporation & Atara Biotherapeutics 85](#_Toc169093198)

[8.1.4 Catalent & RheinCell Therapeutics 85](#_Toc169093199)

[8.1.5 Axol Biosciences & Censo Biotechnologies 86](#_Toc169093200)

[8.1.6 Bayer AG & Bluerock Therapeutics 86](#_Toc169093201)

[8.1.7 Pluriomix & Axiogenesis 86](#_Toc169093202)

[8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector 86](#_Toc169093203)

[8.2.1 Shinobi Therapeutics & Panasonic 88](#_Toc169093204)

[8.2.2 SCG Cell Therapy and A\*STAR 89](#_Toc169093205)

[8.2.3 Charles River Laboratories & Pluristyx, Inc. 89](#_Toc169093206)

[8.2.4 Pluristyx, Inc. & National Resilience, Inc. 89](#_Toc169093207)

[8.2.5 University of Texas & GeneCure 90](#_Toc169093208)

[8.2.6 Heartseed, Inc. & Undisclosed Biotech 90](#_Toc169093209)

[8.2.7 Bluerock Therapeutics & Bit.bio 90](#_Toc169093210)

[8.2.8 Applied Stem Cell, Inc. & CIRM 91](#_Toc169093211)

[8.2.9 Resolution Therapeutics & OmniaBio, Inc. 91](#_Toc169093212)

[8.2.10 REPROCELL, Inc. & CIRM 91](#_Toc169093213)

[8.2.11 REPROCELL, Inc. & BioBridge Global 92](#_Toc169093214)

[8.2.12 Elevate Bio & CIRM 92](#_Toc169093215)

[8.2.13 Evotec & Sernova 92](#_Toc169093216)

[8.2.14 Evotec & Almiral 93](#_Toc169093217)

[8.2.15 Quell Therapeutics & Cellistic 93](#_Toc169093218)

[8.2.16 MDimmune & YiPSCELL 94](#_Toc169093219)

[8.2.17 Edigene & Neukio Biotherapeutics 94](#_Toc169093220)

[8.2.18 Matricelf & Ramot 94](#_Toc169093221)

[8.2.19 Evotec & Boehringer Ingelheim 94](#_Toc169093222)

[8.2.20 Pluristyx, Pancella & Implant Therapeutics 95](#_Toc169093223)

[8.2.21 Century Therapeutics & Bristol Myers Squibb 95](#_Toc169093224)

[8.2.22 Fujifilm Cellular Dynamics & Pheno Vista Biosciences 96](#_Toc169093225)

[8.2.23 Metrion Biosciences & Bioqube Ventures 96](#_Toc169093226)

[8.2.24 Cytovia Therapeutics & Cellectis 96](#_Toc169093227)

[8.2.25 Exacis Biotherapeutics & CCRM 97](#_Toc169093228)

[8.2.26 Cynata Therapeutics & Fujifilm Corporation 97](#_Toc169093229)

[8.2.27 Bone Therapeutics & Implant Therapeutics 97](#_Toc169093230)

[8.2.28 REPROCELL & TEXCELL 98](#_Toc169093231)

[8.2.29 Jacobio & Herbecell 98](#_Toc169093232)

[8.2.30 NeuCyte & KIF1A.ORG 98](#_Toc169093233)

[8.2.31 Kite & Shoreline Biosciences 99](#_Toc169093234)

[8.2.32 Neuropath Therapeutics & Hopstem Biotechnology 99](#_Toc169093235)

[8.2.33 Allele Biotech & Cellatoz 100](#_Toc169093236)

[8.2.34 Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics 100](#_Toc169093237)

[8.2.35 Newcells & Takeda 101](#_Toc169093238)

[8.2.36 Biocentriq & Kytopen 101](#_Toc169093239)

[8.2.37 Fujifilm Cellular Dynamics & Sana Biotechnology 101](#_Toc169093240)

[8.2.38 Evotec & Medical Center Hamburg-Eppdorf (UKE) 101](#_Toc169093241)

[8.2.39 NeuCyte & Seaver Autism Center for Research and Treatment 102](#_Toc169093242)

[8.2.40 Cytovia Therapeutics & National Cancer Institute 102](#_Toc169093243)

[8.2.41 Mogrify & MRC Laboratory of Molecular Biology 102](#_Toc169093244)

[8.3 Venture Capital Funding in iPSC Sector 103](#_Toc169093245)

[8.3.1 Asgard Therapeutics 104](#_Toc169093246)

[8.3.2 Kenai Therapeutics 105](#_Toc169093247)

[8.3.3 Pluristyx 105](#_Toc169093248)

[8.3.4 Fujifilm Cellular Dynamics 105](#_Toc169093249)

[8.3.5 Mogrify Ltd. 106](#_Toc169093250)

[8.3.6 Heartseed, Inc. 106](#_Toc169093251)

[8.3.7 Elevate Bio 107](#_Toc169093252)

[8.3.9 Aspen Neurosciences 107](#_Toc169093253)

[8.3.10 Axol Biosciences 108](#_Toc169093254)

[8.3.11 Thyas, Co. Ltd 108](#_Toc169093255)

[8.3.12 Synthego 108](#_Toc169093256)

[8.3.13 Cellino Biotech, Inc 109](#_Toc169093257)

[8.3.14 Curi Bio 109](#_Toc169093258)

[8.3.15 Ncardia 110](#_Toc169093259)

[8.3.16 Evotec SE 110](#_Toc169093260)

[8.3.17 bit.bio 110](#_Toc169093261)

[8.3.18 Clade Therapeutics 110](#_Toc169093262)

[8.3.19 Shoreline Biosciences 111](#_Toc169093263)

[8.3.20 Kytopen 111](#_Toc169093264)

[8.3.21 Cytovia Therapeutics & CytoLynx 111](#_Toc169093265)

[8.3.22 TreeFrog Therapeutics 112](#_Toc169093266)

[8.3.23 HebeCell Corporation 112](#_Toc169093267)

[8.3.24 Neukio Biotherapeutics 113](#_Toc169093268)

[8.3.25 Stemson Therapeutics 113](#_Toc169093269)

[8.3.26 Vita Therapeutics 113](#_Toc169093270)

[8.3.27 Century Therapeutics 114](#_Toc169093271)

[8.3.28 Heartseed 114](#_Toc169093272)

[8.3.29 Mogrify 114](#_Toc169093273)

[8.3.30 Metrion Biosciences 115](#_Toc169093274)

[8.3.31 Elevate Bio 115](#_Toc169093275)

[8.3.32 Vita Therapeutics 115](#_Toc169093276)

[9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 116](#_Toc169093277)

[9.1 OSKM Cocktail 116](#_Toc169093278)

[9.1.1 Octamer-binding Transcription Factor 4 (Oct4) 117](#_Toc169093279)

[9.1.2 Sry-related Box (SOX) Factor 2 117](#_Toc169093280)

[9.1.3 Kruppel-like Factors (Klf4) 118](#_Toc169093281)

[9.1.4 C-Myc 118](#_Toc169093282)

[9.2 Pluripotency-Associated Transcription Factors and their Functions 118](#_Toc169093283)

[9.2.1 Different Combinations of Factors for Different Cell Sources 120](#_Toc169093284)

[9.3 Delivery of Reprogramming Factors 120](#_Toc169093285)

[9.3.1 Integrating Systems 121](#_Toc169093286)

[9.3.1.1 Retroviral Vectors 122](#_Toc169093287)

[9.3.1.2 Lentiviral Vectors 122](#_Toc169093288)

[9.3.1.3 piggyBack (PB) Transposon Method 123](#_Toc169093289)

[9.3.2 Non-Integrative Delivery Systems 124](#_Toc169093290)

[9.3.2.1 Adenoviral Vectors 124](#_Toc169093291)

[9.3.2.2 Sendai Viral Vectors 125](#_Toc169093292)

[9.3.2.3 Plasmid Vectors 125](#_Toc169093293)

[9.3.2.4 Minicircles 125](#_Toc169093294)

[9.3.2.5 oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1)-based Episomes 125](#_Toc169093295)

[9.3.2.6 RNA Delivery Approach 126](#_Toc169093296)

[9.3.2.7 Proteins 127](#_Toc169093297)

[9.3.3 Comparison of Delivery Methods 127](#_Toc169093298)

[9.4 Genome Editing Technologies in iPSC Generation 129](#_Toc169093299)

[9.4.1 CRISPR/Cas9 129](#_Toc169093300)

[9.5 Available iPSC Lines and their applications 130](#_Toc169093301)

[10. HUMAN IPSC BANKING 132](#_Toc169093302)

[10.1 Major Biobanks Storing iPSCs & iPSC Lines 133](#_Toc169093303)

[10.1.1 RIKEN 134](#_Toc169093304)

[10.1.1.1 Human iPS Cells offered by RIKEN 134](#_Toc169093305)

[10.1.2 WiCell 135](#_Toc169093306)

[10.1.2.1 WiCell’s iPSC Lines 136](#_Toc169093307)

[10.1.3 Fujifilm Cellular Dynamics, Inc. 137](#_Toc169093308)

[10.1.3.1 iPSC Generation 137](#_Toc169093309)

[10.1.4 Sampled 138](#_Toc169093310)

[10.1.4.1 Biobanking Services 139](#_Toc169093311)

[10.1.4.2 Sampled’s iPSC Services 139](#_Toc169093312)

[10.1.5 Coriell Institute for Medical Research 139](#_Toc169093313)

[10.1.5.1 iPSCs at Coriell 140](#_Toc169093314)

[10.1.5.2 Coriell’s Biobank 140](#_Toc169093315)

[10.1.5.2.1 National Institute of General Medical Sciences (NIGMS) 140](#_Toc169093316)

[10.1.5.2.2 National Institute on Aging (NIA) 141](#_Toc169093317)

[10.1.5.2.3 Allen Cell Collection 142](#_Toc169093318)

[10.1.5.2.4 iPSC Collection from Rett Syndrome Research Trust 143](#_Toc169093319)

[10.1.5.2.5 Autism Research Resource 144](#_Toc169093320)

[10.1.5.2.6 HD Community BioRepository 144](#_Toc169093321)

[10.1.5.2.7 CDC Cell and DNA Repository 144](#_Toc169093322)

[10.1.5.2.8 NEI-AREDS Genetic Repository 144](#_Toc169093323)

[10.1.6 European Bank for Induced Pluripotent Stem Cells (EBiSC) 145](#_Toc169093324)

[10.1.6.1 EBiSC Catalogue 145](#_Toc169093325)

[10.1.6.2 EBiSC’s iPSC Banking Service 145](#_Toc169093326)

[10.2 Cell Sources for iPSC Banks 146](#_Toc169093327)

[10.3 Reprogramming Methods in iPSC Banks 147](#_Toc169093328)

[10.4 Ownership and Investments made in iPSC Banks 147](#_Toc169093329)

[11. BIOMEDICAL APPLICATIONS OF IPSCs 150](#_Toc169093330)

[11.1 iPSCs in Basic Research 151](#_Toc169093331)

[11.1.1 To Understand Cell Fate Control 151](#_Toc169093332)

[11.1.2 To Understand Cell Rejuvenation 151](#_Toc169093333)

[11.1.3 To Understand Pluripotency 151](#_Toc169093334)

[11.1.4 To Study Tissue & Organ Development 152](#_Toc169093335)

[11.1.5 To Produce Human Gametes from iPSCs 152](#_Toc169093336)

[11.1.6 Providers of iPSC-Related Services for Researchers 152](#_Toc169093337)

[11.2 Applications of iPSCs in Drug Discovery 154](#_Toc169093338)

[11.2.1 Drugs Tested for Cardiovascular Diseases using iPSCs 155](#_Toc169093339)

[11.2.2 Drugs Tested for Neurological Diseases using iPSC Lines 157](#_Toc169093340)

[11.2.3 Drugs Tested for Rare Diseases using iPSC Lines 159](#_Toc169093341)

[11.3 Applications of iPSCs in Toxicology Studies 160](#_Toc169093342)

[11.3.1 Examples of Drugs Tested for their Toxicity using iPSCs 162](#_Toc169093343)

[11.3.2 Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies 164](#_Toc169093344)

[11.4 Applications of iPSCs in Disease Modeling 165](#_Toc169093345)

[11.4.1 Cardiovascular Diseases Modeled with iPSC-Derived Cells 170](#_Toc169093346)

[11.4.1.1 Percent Utilization of iPSCs for Cardiovascular Disease Modeling 171](#_Toc169093347)

[11.4.2 Modeling Liver Diseases using iPSC-Derived Hepatocytes 172](#_Toc169093348)

[11.4.3 iPSCs in Neurodegenerative Disease Modeling 174](#_Toc169093349)

[11.4.4 iPSC-derived Organoids for Disease Modeling 179](#_Toc169093350)

[11.4.5 Cancer-Derived iPSCs 180](#_Toc169093351)

[11.5 Applications of iPSCs in Cell-Based Therapies 181](#_Toc169093352)

[11.5.2 Companies Focusing only on iPSC-based Therapies 187](#_Toc169093353)

[11.6 Other Novel Applications of iPSCs 187](#_Toc169093354)

[11.6.1 Applications of iPSCs in Tissue Engineering 188](#_Toc169093355)

[11.6.1.1 3D Bioprinting Techniques 188](#_Toc169093356)

[11.6.1.2 Biomaterials 188](#_Toc169093357)

[11.6.1.3 3D Bioprinting Strategies 188](#_Toc169093358)

[11.6.1.4 Bioprinting iPSC-Derived Cells 191](#_Toc169093359)

[11.6.2 iPSCs from Farm Animals 192](#_Toc169093360)

[11.6.2.1 iPSCs Generated from Cattle 192](#_Toc169093361)

[11.6.2.2 iPSCs from Sheep 193](#_Toc169093362)

[11.6.2.3 iPSCs from Goat 194](#_Toc169093363)

[11.6.2.4 iPSCs Generated from Buffalo 195](#_Toc169093364)

[11.6.2.5 iPSC Generation from Avians 196](#_Toc169093365)

[11.6.3 iPSC Lines for the Preservation of Endangered Species of Animals 196](#_Toc169093366)

[11.6.4 iPSCs in Cultured Meat 198](#_Toc169093367)

[12. MARKET ANALYSIS 199](#_Toc169093368)

[12.1 Global Market for iPSCs by Geography 201](#_Toc169093369)

[12.2 Global Market for iPSCs by Technology 203](#_Toc169093370)

[12.3 Global Market for iPSCs by Biomedical Application 205](#_Toc169093371)

[12.4 Global Market for iPSCs by Derived Cell Type 207](#_Toc169093372)

[12.5 Market Drivers 209](#_Toc169093373)

[12.5.1 Current Drivers Impacting the iPSC Market Place 209](#_Toc169093374)

[12.6 Market Restraints 210](#_Toc169093375)

[12.6.1 Economic Issues 210](#_Toc169093376)

[12.6.2 Genomic Instability 210](#_Toc169093377)

[12.6.3 Immunogenicity 210](#_Toc169093378)

[12.6.4 Biobanking 211](#_Toc169093379)

[13. COMPANY PROFILES 212](#_Toc169093380)

[13.1 AcceGen 213](#_Toc169093381)

[13.1.1 ASC-CRISPR iPSC Gene Editing Technology Service 213](#_Toc169093382)

[13.2 Acellta, Ltd. 214](#_Toc169093383)

[13.2.1 Technology 214](#_Toc169093384)

[13.2.1.1 Maxells 214](#_Toc169093385)

[13.2.1.2 Singles 214](#_Toc169093386)

[13.2.1.3 Differentiation 215](#_Toc169093387)

[13.2.1.4 Manufacturing Facility 215](#_Toc169093388)

[13.2.1.5 Services 215](#_Toc169093389)

[13.3 AddGene, Inc. 216](#_Toc169093390)

[13.3.1 Viral Plasmids 216](#_Toc169093391)

[13.4 Allele Biotechnology, Inc. 217](#_Toc169093392)

[13.4.1 Technologies 217](#_Toc169093393)

[13.4.1.1 mRNA Genome Editing 217](#_Toc169093394)

[13.4.1.2 Single Cell Cloning 217](#_Toc169093395)

[13.5 ALSTEM, Inc. 218](#_Toc169093396)

[13.5.1 Cell Line Generation Tools 218](#_Toc169093397)

[13.5.2 Cell Immortalization Kits 218](#_Toc169093398)

[13.5.3 iPSC Kits 218](#_Toc169093399)

[13.5.4 Cell Lines 219](#_Toc169093400)

[13.5.5 Gene Editing 219](#_Toc169093401)

[13.5.6 iPS Cell Lines 220](#_Toc169093402)

[13.5.7 Virus Packaging Tools 220](#_Toc169093403)

[13.6 Altos Labs 221](#_Toc169093404)

[13.6.1 Altos’ Science 221](#_Toc169093405)

[13.7 AMS Biotechnology, Ltd. (AMSBIO) 222](#_Toc169093406)

[13.7.1 Cell Line Products 222](#_Toc169093407)

[13.7.1.1 Disease Models 223](#_Toc169093408)

[13.7.1.2 Viral Production Services 223](#_Toc169093409)

[13.8 Applied StemCell (ASC) 224](#_Toc169093410)

[13.8.1 iPSC-Based Preclinical CRO Services 224](#_Toc169093411)

[13.8.1.1 Reprogramming to Differentiation 224](#_Toc169093412)

[13.8.1.2 Neurotoxicity Screening 225](#_Toc169093413)

[13.8.2 GMP Grade iPSC Services & Products 225](#_Toc169093414)

[13.8.2.1 GMP iPSC 225](#_Toc169093415)

[13.8.2.2 Knock-In Ready GMP TARGATT iPSCs 225](#_Toc169093416)

[13.8.3 GMP TARGATT iPSC-iNK Platform 226](#_Toc169093417)

[13.8.4 CRISPR iPSC Genome Editing Service 226](#_Toc169093418)

[13.8.4.1 CRISPR Knock-In & Point Matation iPS Cell Generation 226](#_Toc169093419)

[13.8.4.2 CRISPR iPSC Gene Knockout 226](#_Toc169093420)

[13.8.4.3 TARGATT Knock-In iPS Cells 227](#_Toc169093421)

[13.8.5 iPSC Generation Services 227](#_Toc169093422)

[13.8.6 iPSC Differentiation Service 227](#_Toc169093423)

[13.8.7 Stem Cell Products 228](#_Toc169093424)

[13.9 Asgard Therapeutics 228](#_Toc169093425)

[13.10 Aspen Neurosciences, Inc. 229](#_Toc169093426)

[13.10.1 Aspen’s Clinical Pipeline 229](#_Toc169093427)

[13.11 Astellas Pharma, Inc. 230](#_Toc169093428)

[13.11.1 Allogeneic Cell Therapy 230](#_Toc169093429)

[13.11.2 Universal Donor Cell Technology 231](#_Toc169093430)

[13.11.3 Astella’s Robust Pipeline 231](#_Toc169093431)

[13.12 Axol Biosciences, Ltd. 233](#_Toc169093432)

[13.12.1 Axol’s Genetically Engineered Disease Lines 233](#_Toc169093433)

[13.12.2 Custom Human iPSC iPSC Services 233](#_Toc169093434)

[13.12.3 Axol’s Products 234](#_Toc169093435)

[13.13 BioCentriq 235](#_Toc169093436)

[13.13.1 LEAP Advanced Therapy Platform 235](#_Toc169093437)

[13.14 Bit.bio 236](#_Toc169093438)

[13.14.1 Therapeutics 236](#_Toc169093439)

[13.14.2 Opti-Ox Reprogramming Technology 237](#_Toc169093440)

[13.14.2.1 ioCells 237](#_Toc169093441)

[13.14.2.2 ioWild Type Cells 237](#_Toc169093442)

[13.14.2.3 ioGlutamatergic Neurons 237](#_Toc169093443)

[13.14.2.4 ioSkeletal Myocytes 238](#_Toc169093444)

[13.14.2.5 ioGABAergic Neurons 238](#_Toc169093445)

[13.14.2.6 ioDisease Models 238](#_Toc169093446)

[13.14.2.7 ioGlutamatergic Neurons50CAGWT 238](#_Toc169093447)

[13.15 BlueRock Therapeutics LP 239](#_Toc169093448)

[13.15.1 BlueRock’s Cell Therapy 239](#_Toc169093449)

[13.15.2 CELL + GENE Platform 239](#_Toc169093450)

[13.15.3 BlueRock’s Cell Therapy Programs 239](#_Toc169093451)

[13.16 BrainXell 241](#_Toc169093452)

[13.16.1 Products 241](#_Toc169093453)

[13.16.2 Custom Service Projects 242](#_Toc169093454)

[13.16.3 In-House Assay Services 242](#_Toc169093455)

[13.17 Cartherics Pty, Ltd. 243](#_Toc169093456)

[13.17.1 Allogeneic CAR Immune Cells 243](#_Toc169093457)

[13.18 Catalent Biologics 244](#_Toc169093458)

[13.18.1 OneBio Integrated Suite 244](#_Toc169093459)

[13.18.2 Drug Substance Development 244](#_Toc169093460)

[13.18.3 Drug Product Development 244](#_Toc169093461)

[13.18.4 Analytical Services 245](#_Toc169093462)

[13.18.5 Catalent’s iPSC Services 245](#_Toc169093463)

[13.19 Cellistic 246](#_Toc169093464)

[13.19.1 Pulse Platform 246](#_Toc169093465)

[13.19.2 Echo Platform 246](#_Toc169093466)

[13.19.3 iPSC-based Allogeneic Approach 246](#_Toc169093467)

[13.19.3.1 Model 1 247](#_Toc169093468)

[13.19.3.2 Model 2 247](#_Toc169093469)

[13.20 CellOrigin Biotech (Hangzhou), Co., Ltd. 248](#_Toc169093470)

[13.21 Celogics, Inc. 249](#_Toc169093471)

[13.21.1 Celo-Cardiomyocytes 249](#_Toc169093472)

[13.22 Cellular Engineering Technologies (CET) 250](#_Toc169093473)

[13.22.1 iPS Cell Reprogramming Methods 250](#_Toc169093474)

[13.22.2 Applications of CET’s Stem Cells 250](#_Toc169093475)

[13.22.2.1 Hypoimmune Cell Lines 250](#_Toc169093476)

[13.22.2.2 Cell Therapy Development 251](#_Toc169093477)

[13.22.2.3 Disease Modeling 251](#_Toc169093478)

[13.22.2.4 Drug Development & Discovery 251](#_Toc169093479)

[13.22.2.5 Regenerative Medicine 251](#_Toc169093480)

[13.22.2.6 Toxicology Studies 252](#_Toc169093481)

[13.22.3 Products 252](#_Toc169093482)

[13.23 Cellusion, Inc. 253](#_Toc169093483)

[13.23.1 Orphan Drug Designation 253](#_Toc169093484)

[13.23.2 Bullous Keratopathy 254](#_Toc169093485)

[13.24 Century Therapeutics, Inc. 255](#_Toc169093486)

[13.24.1 Cell Therapy Platform 255](#_Toc169093487)

[13.24.2 Century’s Product Pipeline 256](#_Toc169093488)

[13.25 Citius Pharmaceuticals, Inc. 257](#_Toc169093489)

[13.25.1 Stem Cell Platform 257](#_Toc169093490)

[13.26 Creative Bioarray 258](#_Toc169093491)

[13.26.1 Pluripotent Stem Cells 258](#_Toc169093492)

[13.26.2 iPSC-Derived Cells 259](#_Toc169093493)

[13.26.3 Services 260](#_Toc169093494)

[13.27 Curi Bio 261](#_Toc169093495)

[13.27.1 Disease Model Development Services 261](#_Toc169093496)

[13.28 Cynata Therapeutics, Ltd. 262](#_Toc169093497)

[13.28.1 Cymerus Platform 262](#_Toc169093498)

[13.28.2 Clinical Development for GvHD 262](#_Toc169093499)

[13.28.3 Osteoarthritis 263](#_Toc169093500)

[13.28.4 ARDS 263](#_Toc169093501)

[13.28.5 Diabetic Wounds 263](#_Toc169093502)

[13.29 Cytovia Therapeutics 264](#_Toc169093503)

[13.29.1 iPSC-derived NK & CAR-NK Cells 264](#_Toc169093504)

[13.30 DefiniGEN 265](#_Toc169093505)

[13.30.1 DefiniGEN’s Platform 265](#_Toc169093506)

[13.30.2 Efficacy Screening Services 265](#_Toc169093507)

[13.30.3 Toxicology Screening 266](#_Toc169093508)

[13.30.4 Disease Models 266](#_Toc169093509)

[13.30.5 iPSC Cell Products 266](#_Toc169093510)

[13.31 Editas Medicine 268](#_Toc169093511)

[13.31.1 SLEEK Gene Editing 268](#_Toc169093512)

[13.31.2 iPSC-Derived NK Cells 268](#_Toc169093513)

[13.32 Editco Bio., Inc. 269](#_Toc169093514)

[13.32.1 Knockout iPS Cell Lines 269](#_Toc169093515)

[13.32.2 Knock-in iPS Cell Lines 269](#_Toc169093516)

[13.33 ElevateBio 270](#_Toc169093517)

[13.33.1 iPSC Technology 270](#_Toc169093518)

[13.34 Elixirgen Scientific, Inc. 271](#_Toc169093519)

[13.34.1 Technology 271](#_Toc169093520)

[13.34.2 Service Offerings 271](#_Toc169093521)

[13.34.3 iPSC Products 272](#_Toc169093522)

[13.35 Eterna Therapeutics 273](#_Toc169093523)

[13.35.1 Gene Editing 273](#_Toc169093524)

[13.35.2 Gene Delivery 273](#_Toc169093525)

[13.36 Evotec AG 274](#_Toc169093526)

[13.36.1 iPS Cell Therapies 274](#_Toc169093527)

[13.36.2 Drug Discovery Services 275](#_Toc169093528)

[13.36.3 Therapeutic Areas 275](#_Toc169093529)

[13.37 Eyestem 276](#_Toc169093530)

[13.37.1 Eyecyte-RPE 276](#_Toc169093531)

[13.37.2 Eyecyte-PRP 277](#_Toc169093532)

[13.37.3 Aircyte-AEC 277](#_Toc169093533)

[13.38 Fate Therapeutics 278](#_Toc169093534)

[13.38.1 iPSC Platform 278](#_Toc169093535)

[13.38.2 iPSC Manufacturing 278](#_Toc169093536)

[13.38.3 Product Pipeline 278](#_Toc169093537)

[13.38.3.1 FT576 279](#_Toc169093538)

[13.38.3.2 FT522 280](#_Toc169093539)

[13.38.3.3 FT819 280](#_Toc169093540)

[13.38.3.4 FT825 281](#_Toc169093541)

[13.38.4 Fate Therapeutics’ Collaborations 282](#_Toc169093542)

[13.38.4.1 ONO Pharmaceutical, Co., Ltd. 282](#_Toc169093543)

[13.38.4.2 Masonic Cancer Center, University of Minnesota 282](#_Toc169093544)

[13.38.4.3 Memorial Sloan-Kettering Cancer Center 282](#_Toc169093545)

[13.38.4.4 Oslo University Hospital 283](#_Toc169093546)

[13.39 FUJIFILM Cellular Dynamics, Inc. 284](#_Toc169093547)

[13.39.1 Products 284](#_Toc169093548)

[13.39.2 FUJIFILM’s Custom Services 285](#_Toc169093549)

[13.39.3 iPSC Disease Modeling 285](#_Toc169093550)

[13.39.4 Safety Pharmacology/Toxicology Testing 286](#_Toc169093551)

[13.40 Gameto 287](#_Toc169093552)

[13.40.1 Fertilo 287](#_Toc169093553)

[13.41 Greenstone Biosciences 288](#_Toc169093554)

[13.42 Heartseed, Inc. 289](#_Toc169093555)

[13.42.1 HS-001: The Lead Product Candidate 289](#_Toc169093556)

[13.42.2 Technologies 289](#_Toc169093557)

[13.42.2.1 Remuscularization 290](#_Toc169093558)

[13.42.2.2 Patented iPSC Production 290](#_Toc169093559)

[13.42.2.3 Differentiation 290](#_Toc169093560)

[13.42.2.4 Purification 291](#_Toc169093561)

[13.42.2.5 Spheroid 291](#_Toc169093562)

[13.43 HebeCell 292](#_Toc169093563)

[13.43.1 ProtoNK 292](#_Toc169093564)

[13.43.2 Retinal Photoreceptor Progenitors 292](#_Toc169093565)

[13.43.3 Nanoproteins 293](#_Toc169093566)

[13.44 Helios K.K. 294](#_Toc169093567)

[13.44.1 Research Activities 295](#_Toc169093568)

[13.45 Hera BioLabs 296](#_Toc169093569)

[13.45.1 Proprietary SRG Rat 296](#_Toc169093570)

[13.45.2 Cas-CLOVER Gene Editing Platform 296](#_Toc169093571)

[13.45.3 The piggyback Transposon System Platform 297](#_Toc169093572)

[13.45.4 Cell Line Development Services 297](#_Toc169093573)

[13.45.5 Custom Cell Line Engineering Services 297](#_Toc169093574)

[13.45.6 Animal Model Creation 297](#_Toc169093575)

[13.45.7 In vivo Research Services 298](#_Toc169093576)

[13.45.7.1 Custom Research Models 298](#_Toc169093577)

[13.45.7.2 Metabolic Disease Models 298](#_Toc169093578)

[13.45.7.3 Xenograft & PDX Services 298](#_Toc169093579)

[13.45.7.4 Pharmacology & Toxicology Services 299](#_Toc169093580)

[13.46 Hopstem Biotechnology 300](#_Toc169093581)

[13.46.1 Pipeline 300](#_Toc169093582)

[13.47 Implant Therapeutics, Inc. 302](#_Toc169093583)

[13.47.1 Services 302](#_Toc169093584)

[13.48 IN8bio 303](#_Toc169093585)

[13.48.1 The DeltEx Platform 303](#_Toc169093586)

[13.48.2 iPSC Gamma-Delta T Cells 304](#_Toc169093587)

[13.49 I Peace, Inc. 305](#_Toc169093588)

[13.49.1 GMP Products 305](#_Toc169093589)

[13.49.2 Custom Manufacturing Services 305](#_Toc169093590)

[13.50 IPS HEART 306](#_Toc169093591)

[13.50.1 IPS HEART’s Approach 306](#_Toc169093592)

[13.50.2 ISX-9 CPC 306](#_Toc169093593)

[13.50.3 GIVI-MPC 307](#_Toc169093594)

[13.51 iPS Portal, Inc. 308](#_Toc169093595)

[13.51.1 Services 308](#_Toc169093596)

[13.51.1.1 Development Services 308](#_Toc169093597)

[13.51.1.2 Business Support Services 309](#_Toc169093598)

[13.52 iPSirius 310](#_Toc169093599)

[13.52.1 iPSirius’ Platform 310](#_Toc169093600)

[13.53 iXCells Biotechnologies 311](#_Toc169093601)

[13.53.1 iPS Cell Products 311](#_Toc169093602)

[13.53.2 Preclinical Services 312](#_Toc169093603)

[13.54 Kenai Therapeutics, Inc. 313](#_Toc169093604)

[13.55 Khloris Biosciences, Inc. 314](#_Toc169093605)

[13.56 Kytopen 315](#_Toc169093606)

[13.56.1 Products 315](#_Toc169093607)

[13.56.1.1 Flowfect Discover 315](#_Toc169093608)

[13.56.1.2 Flowfect TX 315](#_Toc169093609)

[13.56.1.3 Flowfect Connect 316](#_Toc169093610)

[13.57 Laverock Therapeutics 317](#_Toc169093611)

[13.57.1 GEiGS and iPSCs 317](#_Toc169093612)

[13.57.2 Ex Vivo GEiGS-Enabled Cell Therapies 317](#_Toc169093613)

[13.58 Lindville Bio, Ltd. 319](#_Toc169093614)

[13.58.1 Services 319](#_Toc169093615)

[13.59 Lonza Group, Ltd. 321](#_Toc169093616)

[13.59.1 iPSC Manufacturing Expertise 321](#_Toc169093617)

[13.59.2 Nucleofector Technology 321](#_Toc169093618)

[13.60 Matricelf 322](#_Toc169093619)

[13.60.1 Solution to Spinal Cord Injury 322](#_Toc169093620)

[13.61 Megakaryon Corporation 323](#_Toc169093621)

[13.61.1 Production of Platelets from iPSCs 323](#_Toc169093622)

[13.61.2 Development of Megakaryocytes from iPSCs 323](#_Toc169093623)

[13.61.3 Safe Production of Platelets 324](#_Toc169093624)

[13.61.4 Research & Development Pipeline 324](#_Toc169093625)

[13.62 Metrion Biosciences, Ltd. 325](#_Toc169093626)

[13.62.1 Ion Channel High-Throughput Screening 325](#_Toc169093627)

[13.62.2 Clinical QTc/QRS Prediction using hiPSC-Derived Cardiomyocytes 325](#_Toc169093628)

[13.63 Mogrify 326](#_Toc169093629)

[13.63.1 MOGRIFY Platform 326](#_Toc169093630)

[13.63.2 epiMOGRIFY Platform 327](#_Toc169093631)

[13.64 Ncardia Services B.V. 328](#_Toc169093632)

[13.64.1 Ncyte Astrocytes 328](#_Toc169093633)

[13.64.2 Ncyte Endothelial Cells 328](#_Toc169093634)

[13.64.3 Ncyte Neural Mix 329](#_Toc169093635)

[13.64.4 Ncyte Smooth Muscle Cells 329](#_Toc169093636)

[13.64.5 Ncyte vCardiomyocytes 329](#_Toc169093637)

[13.64.6 Custom Disease Modeling Services 329](#_Toc169093638)

[13.64.7 High-Throughput Screening Services 330](#_Toc169093639)

[13.64.8 iPSC-Based Efficacy Assay Services 330](#_Toc169093640)

[13.64.9 iPSC-Based Safety & Toxicity Assays 330](#_Toc169093641)

[13.65 NeuCyte 331](#_Toc169093642)

[13.65.1 Technology 331](#_Toc169093643)

[13.65.2 Drug Discovery 332](#_Toc169093644)

[13.66 Neukio Biotherapeutics 333](#_Toc169093645)

[13.66.1 Allogeneic Immunotherapy Platform 333](#_Toc169093646)

[13.67 Newcells Biotech 334](#_Toc169093647)

[13.67.1 Retina Models 334](#_Toc169093648)

[13.67.2 Retinal Organoids 334](#_Toc169093649)

[13.67.3 Retinal Pigment Epithelium (RPE) 334](#_Toc169093650)

[13.67.4 Kidney Proximal Tubule Cell Model 335](#_Toc169093651)

[13.67.5 Assay-Ready aProximate 335](#_Toc169093652)

[13.67.6 Glomerular Toxicity and Disease Modeling 335](#_Toc169093653)

[13.67.7 Lung Airway Models 336](#_Toc169093654)

[13.67.8 Disease Modeling Services 336](#_Toc169093655)

[13.67.8.1 In vitro Retinal Disease Modeling for Retinal Therapy 336](#_Toc169093656)

[13.67.8.2 in vitro Evaluation of Retinal Toxicity Services 336](#_Toc169093657)

[13.67.8.3 Gene Therapy Services 336](#_Toc169093658)

[13.67.8.4 Drug Transporter Interactions & DDI Services 337](#_Toc169093659)

[13.67.8.5 Cross Species Comparison Services 337](#_Toc169093660)

[13.67.8.6 Kidney Toxicity Services 337](#_Toc169093661)

[13.67.8.7 Kidney Disease Modeling Services 338](#_Toc169093662)

[13.67.8.8 Fibroblast Assay Services 338](#_Toc169093663)

[13.67.8.9 Lung Toxicity Study Services 338](#_Toc169093664)

[13.68 NEXEL, Co., Ltd. 339](#_Toc169093665)

[13.68.1 Products 339](#_Toc169093666)

[13.68.1.1 Cardiosight-S 339](#_Toc169093667)

[13.68.1.2 Hepatosight-S 339](#_Toc169093668)

[13.68.1.3 Neurosight-S 340](#_Toc169093669)

[13.68.2 Curi Bio Systems 340](#_Toc169093670)

[13.68.2.1 Mantarray 340](#_Toc169093671)

[13.68.2.2 Cytostretcher 341](#_Toc169093672)

[13.68.2.3 NanoSurface Plates 341](#_Toc169093673)

[13.68.3 Services 342](#_Toc169093674)

[13.68.3.1 NeXST (Next Xight Screening Test) 342](#_Toc169093675)

[13.68.3.2 Curi Engine SVC 342](#_Toc169093676)

[13.69 Notch Therapeutics 343](#_Toc169093677)

[13.69.1 Technology 343](#_Toc169093678)

[13.69.2 Product Development 344](#_Toc169093679)

[13.70 Orizuru Therapeutics, Inc. 345](#_Toc169093680)

[13.70.1 iCM Project 345](#_Toc169093681)

[13.71 Phenocell SAS 346](#_Toc169093682)

[13.71.1 iPSC-derived RPE Cells for Age-related Macular Degeneration (AMD) 346](#_Toc169093683)

[13.71.2 R&D Solutions for Acne & Hyperseborrhea 346](#_Toc169093684)

[13.71.3 Skin Pigmentation Research & Testing Platform 347](#_Toc169093685)

[13.71.4 Cells & Kits 347](#_Toc169093686)

[13.72 Pluristyx 348](#_Toc169093687)

[13.72.1 The panCELLa Platform 348](#_Toc169093688)

[13.72.2 RTD iPSC & GMP Cell Banks 348](#_Toc169093689)

[13.72.3 Development Services 348](#_Toc169093690)

[13.72.4 Custom Gene Editing 349](#_Toc169093691)

[13.72.5 iPSC GMP Manufacturing Expertise 349](#_Toc169093692)

[13.72.6 Custom Gene Editing 349](#_Toc169093693)

[13.72.7 FailSafe 349](#_Toc169093694)

[13.72.8 iACT Stealth Cells 350](#_Toc169093695)

[13.72.9 Products 350](#_Toc169093696)

[13.72.9.1 PluriBank PSCs 350](#_Toc169093697)

[13.72.9.2 ESI Pluripotent Stem Cells 350](#_Toc169093698)

[13.72.9.3 Wild Type & Disease Affected PSCs 350](#_Toc169093699)

[13.72.10 Differentiated Cells 351](#_Toc169093700)

[13.73 ReNeuron 352](#_Toc169093701)

[13.73.1 Technology Platform 352](#_Toc169093702)

[13.74 Repairon GmbH 353](#_Toc169093703)

[13.74.1 Technology 353](#_Toc169093704)

[13.74.1.1 Engineered Heart Muscle (EHM) 353](#_Toc169093705)

[13.75 REPROCELL USA, Inc. 355](#_Toc169093706)

[13.75.1 Services 355](#_Toc169093707)

[13.75.1.1 Donor Recruitment and Patient-Derived Cells 356](#_Toc169093708)

[13.75.1.2 Example Case Study 356](#_Toc169093709)

[13.75.1.3 Target Cell Isolation 357](#_Toc169093710)

[13.75.1.4 iPSC Reprograming Service 357](#_Toc169093711)

[13.75.1.5 iPSC Expansion, Characterization and Banking Services 357](#_Toc169093712)

[13.75.1.6 Neuronal Differentiation Services 358](#_Toc169093713)

[13.75.1.7 Gene Editing Services 358](#_Toc169093714)

[13.75.2 REPROCELL’s iPSC Products 358](#_Toc169093715)

[13.75.2.1 Stemgent 358](#_Toc169093716)

[13.76 Res Nova Bio, Inc. 359](#_Toc169093717)

[13.76.1 Preclinical Study 359](#_Toc169093718)

[13.77 Sartorius CellGenix GmbH 360](#_Toc169093719)

[13.77.1 Products 360](#_Toc169093720)

[13.78 Shinobi Therapeutics 361](#_Toc169093721)

[13.79 Shoreline Biosciences 362](#_Toc169093722)

[13.79.1 iMACs 362](#_Toc169093723)

[13.80 StemSight 363](#_Toc169093724)

[13.80.1 Technology 363](#_Toc169093725)

[13.81 Stemson Therapeutics 364](#_Toc169093726)

[13.81.1 iPSCs for Hair Follicles 364](#_Toc169093727)

[13.82 Stemina Biomarker Discovery 365](#_Toc169093728)

[13.82.1 Cardio quickPREDICT 365](#_Toc169093729)

[13.82.2 devTOX quickPREDICT 366](#_Toc169093730)

[13.83 Tempo Bioscience, Inc. 367](#_Toc169093731)

[13.83.1 Tempo-iAstro 367](#_Toc169093732)

[13.83.2 Tempo-iBMEC 367](#_Toc169093733)

[13.83.3 Tempo-iCardio 368](#_Toc169093734)

[13.83.4 Tempo-iCort 368](#_Toc169093735)

[13.83.5 Tempo-iDopaNer 368](#_Toc169093736)

[13.83.6 Tempo-iLSEC 369](#_Toc169093737)

[13.83.7 Tempo-iKupffer 369](#_Toc169093738)

[13.83.8 Tempo-iHepStellate 369](#_Toc169093739)

[13.83.9 Tempo-iHep3D 370](#_Toc169093740)

[13.83.10 Tempo-iKer 370](#_Toc169093741)

[13.83.11 Tempo-iKidneyPod 370](#_Toc169093742)

[13.83.12 Tempo-iMel 371](#_Toc169093743)

[13.83.13 Tempo-iMG 371](#_Toc169093744)

[13.83.14 Tempo-iMono 371](#_Toc169093745)

[13.83.15 Tempo-iMotorNer 371](#_Toc169093746)

[13.83.16 Tempo-iMSC 372](#_Toc169093747)

[13.83.17 Tempo-iNStem 372](#_Toc169093748)

[13.83.18 Tempo-iOligo 372](#_Toc169093749)

[13.83.19 Tempo-iOsteo 372](#_Toc169093750)

[13.83.20 Tempo-iPeri 373](#_Toc169093751)

[13.83.21 Tempo-iPhago 373](#_Toc169093752)

[13.83.22 Tempo-iRPE 373](#_Toc169093753)

[13.83.23 Tempo-iSchwann 374](#_Toc169093754)

[13.83.24 Tempo-iSenso 374](#_Toc169093755)

[13.83.25 Tempo StemBank 374](#_Toc169093756)

[13.84 Uncommon (Higher Steaks) 376](#_Toc169093757)

[13.84.1 iPSC-Based Cultured Pork 376](#_Toc169093758)

[13.85 Universal Cells 377](#_Toc169093759)

[13.85.1 Technologies 377](#_Toc169093760)

[13.85.1.1 Recombinant Adeno-Associated Virus 377](#_Toc169093761)

[13.85.1.2 PSCs for Every Organ 378](#_Toc169093762)

[13.85.1.3 Universal Donor Cells 378](#_Toc169093763)

[13.85.1.4 HLA Engineering 378](#_Toc169093764)

[13.86 VCCT, Inc. 379](#_Toc169093765)

[13.86.1 Regenerating RPE Cells 379](#_Toc169093766)

[13.87 ViaCyte, Inc. 380](#_Toc169093767)

[13.87.1 Technology 380](#_Toc169093768)

[13.87.1.1 Autologous Approach 380](#_Toc169093769)

[13.87.1.2 Allogeneic Approach 380](#_Toc169093770)

[13.87.2 Pipeline 381](#_Toc169093771)

[13.88 Vita Therapeutics 382](#_Toc169093772)

[13.88.1 Technology 382](#_Toc169093773)

[13.89 XCell Science 384](#_Toc169093774)

[13.89.1 Control Lines 384](#_Toc169093775)

[13.89.1.1 XCL-1 385](#_Toc169093776)

[13.89.1.2 XCL-6 385](#_Toc169093777)

[13.89.2 Cell Products 385](#_Toc169093778)

[13.89.2.1 Control Lines 385](#_Toc169093779)

[13.89.2.2 Knock-out Lines 386](#_Toc169093780)

[13.89.2.3 Reporter Lines 386](#_Toc169093781)

[13.89.3 Services 386](#_Toc169093782)

[13.90 Yashraj Biotechnology, Ltd. 387](#_Toc169093783)

[13.90.1 iPSC Products 387](#_Toc169093784)

[13.90.2 Contract Research Services 387](#_Toc169093785)

**INDEX OF FIGURES**

[FIGURE 3.1: Development of iPSC-based Autologous Cell Therapy for Canavan Disease 24](#_Toc169093786)

[FIGURE 3.2: Manufacturing Timeline for Autologous iPSC-derived Cell Products 26](#_Toc169093787)

[FIGURE 3.3: Cost of iPSC Production 27](#_Toc169093788)

[FIGURE 3.4: Technical Set Up of the Stem Cell Factory (SCF) 28](#_Toc169093789)

[FIGURE 3.5: Development of iPSC-based Allogeneic Cell Therapy 29](#_Toc169093790)

[FIGURE 3.6: Share of iPSC-based Research within the Overall Stem Cell Industry 30](#_Toc169093791)

[FIGURE 3.7: Major Focus Areas of iPSC Companies 31](#_Toc169093792)

[FIGURE 3.8: Relative use of iPSC-derived Cell Types in Toxicology Studies 33](#_Toc169093793)

[FIGURE 3.9: Comparison of Lipofection and Nucleofection Technologies 36](#_Toc169093794)

[FIGURE 5.1: No. of Research Publications on iPSC in PubMed.gov, 2010-May 29, 2024 46](#_Toc169093795)

[FIGURE 5.2: Pubmed Publications on Pathophysiological Research using iPSCs 47](#_Toc169093796)

[FIGURE 5.3: PubMed Publications on Reprogramming Somatic Cells 48](#_Toc169093797)

[FIGURE 5.4: No. of PubMed Papers on iPSC Differentiation 49](#_Toc169093798)

[FIGURE 5.5: PubMed Papers on the use of iPSCs in Drug Discovery 50](#_Toc169093799)

[FIGURE 5.6: PubMed Papers on iPSC-based Cell Therapy 51](#_Toc169093800)

[FIGURE 5.7: Percent Share of Published Articles by Disease Type 52](#_Toc169093801)

[FIGURE 5.8: Percent Share of Articles by Country 53](#_Toc169093802)

[FIGURE 6.1: Number of iPSC Patents Filed by Year, 2000-May 5, 2024 54](#_Toc169093803)

[FIGURE 7.1: Number of Clinical Trials by Year 66](#_Toc169093804)

[FIGURE 7.2: iPSC Clinical Trials by Design, May 2024 68](#_Toc169093805)

[FIGURE 7.3: Therapeutic & Non-Therapeutic iPSC Clinical Trials 68](#_Toc169093806)

[FIGURE 7.4: Non-Therapeutic Clinical Trials by Use 69](#_Toc169093807)

[FIGURE 7.5: Percent Share of Diseases Targeted by Therapeutic Studies 70](#_Toc169093808)

[FIGURE 7.6: Share of Autologous & Allogeneic iPSCs in Clinical Studies 71](#_Toc169093809)

[FIGURE 7.7: iPSC Clinical Trials by Phase of Study 74](#_Toc169093810)

[FIGURE 7.8: iPSC Clinical Trials by Funder Type 74](#_Toc169093811)

[FIGURE 9.1: The Roles of OSKM Factors in the Induction of iPSCs 117](#_Toc169093812)

[FIGURE 9.2: Delivery Methods for iPSC Induction 121](#_Toc169093813)

[FIGURE 9.3: Schematic of Retroviral Delivery Method 122](#_Toc169093814)

[FIGURE 9.4: Schematic of Lentiviral Delivery Method 123](#_Toc169093815)

[FIGURE 9.5: Schematic of piggyBack Transposon Delivery Method 123](#_Toc169093816)

[FIGURE 9.6: Shematic of Adenoviral Vector Delivery 124](#_Toc169093817)

[FIGURE 9.7: oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1)-based Episomes 126](#_Toc169093818)

[FIGURE 9.8: RNA Delivery Approach 126](#_Toc169093819)

[FIGURE 9.9: Protein Delivery 127](#_Toc169093820)

[FIGURE 10.1: PubMed Citations for iPSCs and iPSC Lines registered in hPSCreg 132](#_Toc169093821)

[FIGURE 10.1: Disease States represented by NIGMS Cell Lines 141](#_Toc169093822)

[FIGURE 10.2: Subject Age Range in Collections 142](#_Toc169093823)

[FIGURE 11.1: Biomedical Applications of iPSCs 150](#_Toc169093824)

[FIGURE 11.1: Advantages of iPSC usage in Drug Discovery 154](#_Toc169093825)

[FIGURE 11.2: iPSCs and their Potential for Toxicity Testing and Drug Screening 161](#_Toc169093826)

[FIGURE 11.3: Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies 164](#_Toc169093827)

[FIGURE 11.4: Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling 172](#_Toc169093828)

[FIGURE 11.5: Techniques used for iPSC Bioprinting 189](#_Toc169093829)

[FIGURE 12.1: Estimated Global Market for iPSCs by Geography, 2023-2030 202](#_Toc169093830)

[FIGURE 12.2: Estimated Global Market for iPSCs by Technology, 2023-2030 204](#_Toc169093831)

[FIGURE 12.3: Estimated Global Market for iPSCs by Biomedical Application, 2023-2030 207](#_Toc169093832)

[FIGURE 12.4: Global Market for iPSCs by Derived Cell Type, 2023 208](#_Toc169093833)

[FIGURE 13.1: dCas9-VPR System 220](#_Toc169093834)

[FIGURE 13.2: Universal Donor Cell Technology 231](#_Toc169093835)

[FIGURE 13.3: Century’s Approach to iPSC Therapy 255](#_Toc169093836)

[FIGURE 13.4: FT576 279](#_Toc169093837)

[FIGURE 13.5: FT522 280](#_Toc169093838)

[FIGURE 13.6: FT819 281](#_Toc169093839)

[FIGURE 13.7: FT825 281](#_Toc169093840)

[FIGURE 13.8: Developing iPSC Neurons by SynFire Technology 332](#_Toc169093841)

[FIGURE 13.9: Mantarray Instrument 340](#_Toc169093842)

[FIGURE 13.10: Cytostretcher 341](#_Toc169093843)

[FIGURE 13.11: NanoSurface Plate 341](#_Toc169093844)

[FIGURE 13.12: Repairon’s Engineered Heart Muscle (EHM) 354](#_Toc169093845)

[FIGURE 13.13: REPROCELL’s Example Case Study: Alzheimer’s Disese 356](#_Toc169093846)

[FIGURE 13.14: Cardio quickPREDICT Process 366](#_Toc169093847)

[FIGURE 13.15: devTOX quickPREDICT Process 366](#_Toc169093848)

**INDEX OF TABLES**

[TABLE 3.1: Examples of Autologous iPSC-derived Cell Therapies in Development 25](#_Toc169093849)

[TABLE 3.2: Examples of Clinical Trials involving Allogeneic iPSCs 30](#_Toc169093850)

[TABLE 3.3: Commercially Available iPSC-derived Cell Types 32](#_Toc169093851)

[TABLE 3.4: iPSC-derived Cell Types used in Clinical Trials 34](#_Toc169093852)

[TABLE 4.1: Timeline of Important Milestones Reached in iPSC Industry 39](#_Toc169093853)

[TABLE 5.1: No. of Research Publications on iPSC in PubMed.gov, 2006-June 1, 2024 46](#_Toc169093854)

[TABLE 6.1: iPSC Patent Applications by Jurisdiction as of May 5, 2024 55](#_Toc169093855)

[TABLE 6.2: Patent Applicants as of May 5, 2024 56](#_Toc169093856)

[TABLE 6.2: (CONTINUED) 57](#_Toc169093857)

[TABLE 6.2: (CONTINUED) 58](#_Toc169093858)

[TABLE 6.3: iPSC Patent Inventors 59](#_Toc169093859)

[TABLE 6.3: (CONTINUED) 60](#_Toc169093860)

[TABLE 6.3: (CONTINUED) 61](#_Toc169093861)

[TABLE 6.4: iPSC Patent Owners 62](#_Toc169093862)

[TABLE 6.4: (CONTINUED) 63](#_Toc169093863)

[TABLE 6.4: (CONTINUED) 64](#_Toc169093864)

[TABLE 6.5: Legal Status of iPSC Patents 65](#_Toc169093865)

[TABLE 7.1: Recruitment Status of iPSC Clinical Trials, May 2, 2024 67](#_Toc169093866)

[TABLE 7.2: Examples of iPSC-based Therapeutic Interventional Studies 71](#_Toc169093867)

[TABLE 7.2: (CONTINUED) 72](#_Toc169093868)

[TABLE 7.2: (CONTINUED) 73](#_Toc169093869)

[TABLE 7.3: The Promising iPSC-based Product Candidates Developed across the World 76](#_Toc169093870)

[TABLE 7.4: Examples of Key iPSC-based Preclinical Studies 79](#_Toc169093871)

[TABLE 8.1: M&A in iPSC Sector 84](#_Toc169093872)

[TABLE 8.2: Partnership/Collaboration & Licensing Deals in iPSC Sector, 2021-May 2024 87](#_Toc169093873)

[TABLE 8.2: (CONTINUED) 88](#_Toc169093874)

[TABLE 8.3: Venture Capital Funding in iPSC Sector, 2021-May 2024 103](#_Toc169093875)

[TABLE 8.3: (CONTINUED) 104](#_Toc169093876)

[TABLE 9.1: Pluripotency-Associated Transcription Factors and their Functions 119](#_Toc169093877)

[TABLE 9.2: Diffewrent Combinations of Factors for Different Cell Sources 120](#_Toc169093878)

[TABLE 9.3: Comparison of Delivery Methods of Reprogramming Factors 128](#_Toc169093879)

[TABLE 9.4: iPSC Disease Models Generated by CRISPR/Cas9 130](#_Toc169093880)

[TABLE 9.5: Available iPSC lines and their Major Applications 130](#_Toc169093881)

[TABLE 9.5: (CONTINUED) 131](#_Toc169093882)

[TABLE 10.1: Major Biobanks Storing iPSCs & iPSC Lines 133](#_Toc169093883)

[TABLE 10.2: Disease-Specific iPSCs offered by RIKEN 135](#_Toc169093884)

[TABLE 10.3: Types of iPS Cell Lines available with WiCell – a Sample 136](#_Toc169093885)

[TABLE 10.4: The Four California Institutions recruiting Tissue Donors 137](#_Toc169093886)

[TABLE 10.5: iPSC Disease Samples with FCDI 138](#_Toc169093887)

[TABLE 10.6: Examples of Allen’s Fluorescently Tagged hiPSC lines 143](#_Toc169093888)

[TABLE 10.7: Rett Syndrome Trust’s iPSC Collection 143](#_Toc169093889)

[TABLE 10.8: Cell Sources & Reprogramming Methods for iPSC Banks 146](#_Toc169093890)

[TABLE 10.9: Ownership of iPSC Banks and the Investments Made 149](#_Toc169093891)

[TABLE 11.1: Providers of iPSC-Related Services and Products for Researchers 153](#_Toc169093892)

[TABLE 11.2: Drugs Tested for Cardiovascular Diseases using iPSCs 155](#_Toc169093893)

[TABLE 11.2: (CONTINUED) 156](#_Toc169093894)

[TABLE 11.3: Drugs Tested for Neurological Diseases using iPSC Lines 157](#_Toc169093895)

[TABLE 11.3: (CONTINUED) 158](#_Toc169093896)

[TABLE 11.4: Drugs Tested for Rare Diseases using iPSC Lines 159](#_Toc169093897)

[TABLE 11.4: (CONTINUED) 160](#_Toc169093898)

[TABLE 11.5: Examples of Drugs Tested for their Toxicity using iPSC-Derved Cell Lines 162](#_Toc169093899)

[TABLE 11.5: (CONTINUED) 163](#_Toc169093900)

[TABLE 11.5: (CONTINUED) 164](#_Toc169093901)

[TABLE 11.6: Published Human iPSC Models 165](#_Toc169093902)

[TABLE 11.6: (CONTINUED) 166](#_Toc169093903)

[TABLE 11.6: (CONTINUED) 167](#_Toc169093904)

[TABLE 11.6: (CONTINUED) 168](#_Toc169093905)

[TABLE 11.6: (CONTINUED) 169](#_Toc169093906)

[TABLE 11.6: (CONTINUED) 170](#_Toc169093907)

[TABLE 11.7: Partial List of Cardiovascular & other Diseases Modeled using iPSCs 171](#_Toc169093908)

[TABLE 11.8: Liver Diseases Modeled using iPSCs 173](#_Toc169093909)

[TABLE 11.8: (CONTINUED) 174](#_Toc169093910)

[TABLE 11.9: Examples of iPSC-Based Neurodegenerative Diseae Modeling 175](#_Toc169093911)

[TABLE 11.9: (CONTINUED) 176](#_Toc169093912)

[TABLE 11.9: (CONTINUED) 177](#_Toc169093913)

[TABLE 11.9: (CONTINUED) 178](#_Toc169093914)

[TABLE 11.10: Organoid Types and Diseae Modeling Applications 179](#_Toc169093915)

[TABLE 11.11: Examples of Cancer-Derived iPSCs 180](#_Toc169093916)

[TABLE 11.12: Major Sponsors of iPSC-based Cell Therapies 181](#_Toc169093917)

[TABLE 11.13: Selected Interventional Clinical Trials of iPSC-Based Cell Therapy 182](#_Toc169093918)

[TABLE 11.13: (CONTINUED) 183](#_Toc169093919)

[TABLE 11.13: (CONTINUED) 184](#_Toc169093920)

[TABLE 11.13: (CONTINUED) 185](#_Toc169093921)

[TABLE 11.13: (CONTINUED) 186](#_Toc169093922)

[TABLE 11.14: Companies focusing only on iPSC-based Therapies 187](#_Toc169093923)

[TABLE 11.15: Features of Different iPSC Bioprinting Techniques 190](#_Toc169093924)

[TABLE 11.16: Bioprinting of iPSC-Derived Cells 191](#_Toc169093925)

[TABLE 11.17: iPSCs Generation from Cattle 192](#_Toc169093926)

[TABLE 11.17: (CONTINUED) 193](#_Toc169093927)

[TABLE 11.18: iPSCs Generation from Sheep 194](#_Toc169093928)

[TABLE 11.19: iPSCs Generation from Goat 195](#_Toc169093929)

[TABLE 11.20: iPSCs Generation from Buffalo 195](#_Toc169093930)

[TABLE 11.21: iPSC Generation from Avians 196](#_Toc169093931)

[TABLE 11.22: Timeline of Development of iPSCs Generated from Domestic & Wild Animals 197](#_Toc169093932)

[TABLE 12.1: Estimated Global Market for iPSCs by Geography, 2023-2030 202](#_Toc169093933)

[TABLE 12.2: Estimated Global Market for iPSCs by Technology, 2023-2030 204](#_Toc169093934)

[TABLE 12.3: Estimated Global Market for iPSCs by Biomedical Application, 2023-2030 206](#_Toc169093935)

[TABLE 12.4: Global Market for iPSCs by Derived Cell Type, 2023-2030 208](#_Toc169093936)

[TABLE 13.1: Aspen’s Clinical Pipeline 229](#_Toc169093937)

[TABLE 13.2: Astella’s Robust & Competitive Pipeline 232](#_Toc169093938)

[TABLE 13.3: Bit.bio’s Cell Therapy Pipeline 236](#_Toc169093939)

[TABLE 13.4: BlueRock’s Pipeline of Cell Therapy Products 240](#_Toc169093940)

[TABLE 13.5: Cartheric’s R&D Pipeline 243](#_Toc169093941)

[TABLE 13.6: CellOrigin’s R&D Pipeline 248](#_Toc169093942)

[TABLE 13.7: Cellusion’s Pipeline 254](#_Toc169093943)

[TABLE 13.8: Century’s Pipeline Products 256](#_Toc169093944)

[TABLE 13.9: Cytovia’s iPSC-Derived CAR-iNK Product Pipeline 264](#_Toc169093945)

[TABLE 13.10: Eterna’s R&D Pipeline 273](#_Toc169093946)

[TABLE 13.11: Eyestem’s Product Pipeline 276](#_Toc169093947)

[TABLE 13.12: Fate Therapeutic’s Product Pipeline 279](#_Toc169093948)

[TABLE 13.13: Examples of Greenstone’s iPSC Line Collections 288](#_Toc169093949)

[TABLE 13.14: HebeCell’s Product Pipeline 293](#_Toc169093950)

[TABLE 13.15: Helio’s Research & Development Status 294](#_Toc169093951)

[TABLE 13.16: Hopstem’s Product Pipeline 301](#_Toc169093952)

[TABLE 13.17: IPS HEART’s R&D Pipeline 307](#_Toc169093953)

[TABLE 13.18: iPSirius’ R&D Pipeline 310](#_Toc169093954)

[TABLE 13.19: Kenai Therapeutic’s Pipeline 313](#_Toc169093955)

[TABLE 13.20: Khloris Biosciences’ iPSC-Based Clinical Programs 314](#_Toc169093956)

[TABLE 13.21: Laverock’s R&D Pipeline 318](#_Toc169093957)

[TABLE 13.22: Megakaryon’s Research & Development Pipeline 324](#_Toc169093958)

[TABLE 13.23: NEXEL Pipeline 342](#_Toc169093959)

[TABLE 13.24: Notch Therapeutic’s R&D Pipeline 344](#_Toc169093960)

[TABLE 13.25: Available Stemgent iPSCs with REPROCELL 359](#_Toc169093961)

[TABLE 13.26: Shinobi Therapeutics’ Product Pipeline 361](#_Toc169093962)

[TABLE 13.27: ViaCyte’s Product Pipeline 381](#_Toc169093963)

[TABLE 13.28: Vita Therapeutic’s R&D Pipeline 383](#_Toc169093964)

**About BioInformant**

Founded in 2006, BioInformant.com is a U.S. market research firm that attracts an online readership of nearly one million readers per year. As the first and only market research firm to specialize in the stem cell industry, BioInformant’s research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. BioInformant is unusual because it has been tracking the iPSC industry since it first emerged in 2006 (18+ years).

Headquartered near Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), U.S. FDA, Maryland Biotech Corridor, and policy makers on Capitol Hill.

Serving all-star clients that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in cell therapy industry data.